{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T02:35:27Z","timestamp":1794105327544,"version":"4.8.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 112-2314-B-002-210-MY3"],"award-info":[{"award-number":["NSTC 112-2314-B-002-210-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ophtha.2025.07.009","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T16:45:08Z","timestamp":1753116308000},"page":"1304-1316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and Drug Interactions of Glaucoma Medications"],"prefix":"10.1016","volume":"132","author":[{"given":"Yun","family":"Hsia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Chia","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehn-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsing-Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2461-474X","authenticated-orcid":false,"given":"Yu-Kang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.ophtha.2025.07.009_bib1","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ophtha.2025.07.009_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.exer.2017.02.005","article-title":"Biomechanical aspects of axonal damage in glaucoma: a brief review","volume":"157","author":"Stowell","year":"2017","journal-title":"Exp Eye Res"},{"issue":"4","key":"10.1016\/j.ophtha.2025.07.009_bib3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S1350-9462(02)00008-3","article-title":"The impact of ocular blood flow in glaucoma","volume":"21","author":"Flammer","year":"2002","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"10.1016\/j.ophtha.2025.07.009_bib4","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ophtha.2011.11.003","article-title":"Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement","volume":"119","author":"Chang","year":"2012","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ophtha.2025.07.009_bib5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2020.21899","article-title":"Glaucoma in adults\u2014screening, diagnosis, and management: a review","volume":"325","author":"Stein","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ophtha.2025.07.009_bib6","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.ophtha.2011.01.047","article-title":"Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study","volume":"118","author":"Musch","year":"2011","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ophtha.2025.07.009_bib7","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2025.07.009_bib8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","article-title":"Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis","volume":"123","author":"Li","year":"2016","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ophtha.2025.07.009_bib9","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/bjophthalmol-2020-317262","article-title":"Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis","volume":"106","author":"Harasymowycz","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ophtha.2025.07.009_bib10","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0161-6420(01)00873-9","article-title":"Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery","volume":"108","author":"Lichter","year":"2001","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ophtha.2025.07.009_bib11","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.ophtha.2018.04.040","article-title":"Rho kinase inhibitors as a novel treatment for glaucoma and ocular hypertension","volume":"125","author":"Tanna","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.07.009_bib12","article-title":"Topical medication therapy for glaucoma and ocular hypertension","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.ophtha.2025.07.009_bib13","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1111\/aos.13568","article-title":"Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis","volume":"96","author":"Li","year":"2018","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2025.07.009_bib14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/ICU.0000000000000134","article-title":"Medical therapy for glaucoma: what to add after a prostaglandin analogs?","volume":"26","author":"Tanna","year":"2015","journal-title":"Curr Opin Ophthalmol"},{"issue":"suppl 1","key":"10.1016\/j.ophtha.2025.07.009_bib15","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.survophthal.2008.08.011","article-title":"A review of additivity to prostaglandin analogs: fixed and unfixed combinations","volume":"53","author":"Tabet","year":"2008","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.07.009_bib16","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.ophtha.2025.07.009_bib17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ophtha.2025.07.009_bib18","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.ophtha.2025.07.009_bib19","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1177\/0272989X14545789","article-title":"Use of generalized linear mixed models for network meta-analysis","volume":"34","author":"Tu","year":"2014","journal-title":"Med Decis Making"},{"issue":"3","key":"10.1016\/j.ophtha.2025.07.009_bib20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0962280207080643","article-title":"Evaluation of networks of randomized trials","volume":"17","author":"Salanti","year":"2008","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.ophtha.2025.07.009_bib21","article-title":"Network meta-analysis: application and practice using R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol Health"},{"issue":"12","key":"10.1016\/j.ophtha.2025.07.009_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115065","article-title":"Network meta-analysis using R: a review of currently available automated packages","volume":"9","author":"Neupane","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ophtha.2025.07.009_bib23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.ophtha.2025.07.009_bib24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.ophtha.2025.07.009_bib25","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/bimj.201800167","article-title":"Network meta-analysis of multicomponent interventions","volume":"62","author":"R\u00fccker","year":"2020","journal-title":"Biom J"},{"issue":"7414","key":"10.1016\/j.ophtha.2025.07.009_bib26","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ophtha.2025.07.009_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.ophtha.2025.07.009_bib28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Res Synth Methods"},{"issue":"4","key":"10.1016\/j.ophtha.2025.07.009_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.ophtha.2025.07.009_bib30","article-title":"CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst Rev"},{"issue":"29","key":"10.1016\/j.ophtha.2025.07.009_bib31","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.1002\/sim.3427","article-title":"Meta-analysis of skewed data: combining results reported on log-transformed or raw scales","volume":"27","author":"Higgins","year":"2008","journal-title":"Stat Med"},{"issue":"10","key":"10.1016\/j.ophtha.2025.07.009_bib32","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1089\/jop.2023.0058","article-title":"Clinical efficacy of omidenepag isopropyl for primary open-angle glaucoma, normal tension glaucoma, or ocular hypertension: a meta-analysis","volume":"39","author":"Kuo","year":"2023","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2025.07.009_bib33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajo.2020.06.003","article-title":"Omidenepag isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension: the phase 3 AYAME study","volume":"220","author":"Aihara","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ophtha.2025.07.009_bib34","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1007\/s40123-023-00820-y","article-title":"Rho-kinase inhibitors as emerging targets for glaucoma therapy","volume":"12","author":"Wang","year":"2023","journal-title":"Ophthalmol Ther"},{"issue":"6","key":"10.1016\/j.ophtha.2025.07.009_bib35","article-title":"Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension","volume":"6","author":"Clement","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.ophtha.2025.07.009_bib36","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1080\/14740338.2020.1826928","article-title":"Current and emerging fixed combination therapies in glaucoma: a safety and tolerability review","volume":"19","author":"Konstas","year":"2020","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.1016\/j.ophtha.2025.07.009_bib37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/IJG.0b013e31815072fe","article-title":"Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost","volume":"17","author":"Miura","year":"2008","journal-title":"J Glaucoma"},{"issue":"7","key":"10.1016\/j.ophtha.2025.07.009_bib38","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ophtha.2007.03.012","article-title":"Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%","volume":"114","author":"Feldman","year":"2007","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ophtha.2025.07.009_bib39","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.ophtha.2009.03.050","article-title":"Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs","volume":"116","author":"Bournias","year":"2009","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ophtha.2025.07.009_bib40","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/112067210601600606","article-title":"The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma","volume":"16","author":"Holl\u00f3","year":"2006","journal-title":"Eur J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ophtha.2025.07.009_bib41","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00417-011-1650-8","article-title":"Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension","volume":"249","author":"Pfeiffer","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.07.009_bib42","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3389\/fphar.2019.00679","article-title":"Efficacy and safety of brinzolamide as add-on to prostaglandin analogues or \u03b2-blocker for glaucoma and ocular hypertension: a systematic review and meta-analysis","volume":"10","author":"Liu","year":"2019","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.ophtha.2025.07.009_bib43","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.clinthera.2006.04.007","article-title":"A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension","volume":"28","author":"Reis","year":"2006","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.ophtha.2025.07.009_bib44","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1167\/iovs.13-12717","article-title":"Nonpigmented ciliary epithelial cells respond to acetazolamide by a soluble adenylyl cyclase mechanism","volume":"55","author":"Shahidullah","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.ophtha.2025.07.009_bib45","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1006\/exer.1996.0119","article-title":"Prostaglandin F2 alpha and its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and other mammalian species","volume":"63","author":"Yousufzai","year":"1996","journal-title":"Exp Eye Res"},{"issue":"2","key":"10.1016\/j.ophtha.2025.07.009_bib46","doi-asserted-by":"crossref","first-page":"60","DOI":"10.5483\/BMBRep.2017.50.2.200","article-title":"Role of cyclic AMP in the eye with glaucoma","volume":"50","author":"Shim","year":"2017","journal-title":"BMB Rep"},{"issue":"10","key":"10.1016\/j.ophtha.2025.07.009_bib47","first-page":"1189","article-title":"Pharmacological effects of topical timolol in the rabbit eye","volume":"19","author":"Bartels","year":"1980","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025004439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025004439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:39:21Z","timestamp":1774859961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642025004439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0161642025004439"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.07.009","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Drug Interactions of Glaucoma Medications","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}